NCT04466345View on ClinicalTrials.gov

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

December 27, 2024

Study Completion Date

December 27, 2024

Conditions
Major Depressive Disorder
Interventions
BIOLOGICAL

Semaglutide

3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks

BIOLOGICAL

Placebo

Semaglutide placebo capsules

Trial Locations (1)

M5T 2S8

Toronto Western Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT04466345 - Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder | Biotech Hunter | Biotech Hunter